000274067 001__ 274067
000274067 005__ 20250119000318.0
000274067 0247_ $$2doi$$a10.1002/trc2.70028
000274067 0247_ $$2pmid$$apmid:39759949
000274067 0247_ $$2pmc$$apmc:PMC11696024
000274067 0247_ $$2altmetric$$aaltmetric:172970902
000274067 037__ $$aDZNE-2025-00048
000274067 041__ $$aEnglish
000274067 082__ $$a610
000274067 1001_ $$00000-0002-5280-1075$$aBrettschneider, Christian$$b0
000274067 245__ $$aCost-effectiveness of a multicomponent intervention against cognitive decline.
000274067 260__ $$aHoboken, NJ$$bWiley$$c2025
000274067 3367_ $$2DRIVER$$aarticle
000274067 3367_ $$2DataCite$$aOutput Types/Journal article
000274067 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1736940770_13620
000274067 3367_ $$2BibTeX$$aARTICLE
000274067 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000274067 3367_ $$00$$2EndNote$$aJournal Article
000274067 520__ $$aThe societal costs of dementia and cognitive decline are substantial and likely to increase during the next decades due to the increasing number of people in older age groups. The aim of this multicenter cluster-randomized controlled trial was to assess the cost-effectiveness of a multi-domain intervention to prevent cognitive decline in older people who are at risk for dementia.We used data from a multi-centric, two-armed, cluster-randomized controlled trial (AgeWell.de trial, ID: DRKS00013555). Eligible participants with increased dementia risk at baseline (Cardiovascular Risk Factors, Aging, and Incidence of Dementia/CAIDE Dementia Risk Score ≥ 9), 60-77 years of age, were recruited by their general practitioners, and assigned randomly to a multi-domain lifestyle intervention or general health advice. We performed a cost-effectiveness analysis from the societal perspective. The time horizon was 2 years. Health care utilization was measured using the 'Questionnaire for Health-Related Resource Use in Older Populations.' As effect measure, we used quality-adjusted life-years (QALYs) based on the 5-level EQ-5D version (EQ-5D-5L). We calculated the incremental cost-effectiveness ratios (ICER) and cost-effectiveness acceptability curves (CEAC) using the net-benefit approach. Exploratory analyses considering women and the EQ visual analogue scale (EQ VAS) were conducted.Data were available for 819 participants (mean age 69.0 [standard deviation (SD)5-level EQ-5D version 4.9]); 378 were treated in the intervention group and 441 in the control group. The participants in the intervention group caused higher costs (+€445.88 [SD: €1,244.52]) and gained additional effects (+0.026 QALY [SD: 0.020]) compared to the participants in the control group (the difference was statistically significant). The ICER was €17,149.23/QALY. The CEAC showed that the probability of the intervention being cost-effective was moderate, reaching 59% at a willingness-to-pay (WTP) of €50,000/QALY. The exploratory analyses showed promising results, especially in the female subsample.Considering aspects like the WTP and the limited time horizon, the multi-domain intervention was cost-effective compared to general health advice.The first German randomized controlled trial (RCT) evaluating a multicomponent approach against cognitive decline.We found a favorable incremental cost-effectiveness ratio.The probability of cost-effectiveness reached 78.6%.Women could be an important target group.A longer time horizon is needed.
000274067 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000274067 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000274067 650_7 $$2Other$$aRCT
000274067 650_7 $$2Other$$acognitive decline
000274067 650_7 $$2Other$$acost‐effectiveness analysis
000274067 650_7 $$2Other$$adementia
000274067 650_7 $$2Other$$amulticomponent intervention
000274067 650_7 $$2Other$$aolder individuals
000274067 650_7 $$2Other$$arisk factors
000274067 7001_ $$aBuczak-Stec, Elżbieta$$b1
000274067 7001_ $$aLuppa, Melanie$$b2
000274067 7001_ $$aZülke, Andrea$$b3
000274067 7001_ $$0P:(DE-2719)2810763$$aMichalowsky, Bernhard$$b4$$udzne
000274067 7001_ $$0P:(DE-2719)9001134$$aRädke, Anika$$b5$$udzne
000274067 7001_ $$aBauer, Alexander$$b6
000274067 7001_ $$aBrütting, Christine$$b7
000274067 7001_ $$aKosilek, Robert P$$b8
000274067 7001_ $$aZöllinger, Isabel$$b9
000274067 7001_ $$aDöhring, Juliane$$b10
000274067 7001_ $$aWilliamson, Martin$$b11
000274067 7001_ $$aWiese, Birgitt$$b12
000274067 7001_ $$0P:(DE-2719)2000040$$aHoffmann, Wolfgang$$b13$$udzne
000274067 7001_ $$aFrese, Thomas$$b14
000274067 7001_ $$aGensichen, Jochen$$b15
000274067 7001_ $$aKaduszkiewicz, Hanna$$b16
000274067 7001_ $$0P:(DE-2719)2290613$$aThyrian, Jochen René$$b17$$udzne
000274067 7001_ $$aRiedel-Heller, Steffi G$$b18
000274067 7001_ $$aKönig, Hans-Helmut$$b19
000274067 7001_ $$aDE study group, AGEWELL.$$b20$$eCollaboration Author
000274067 773__ $$0PERI:(DE-600)2832891-7$$a10.1002/trc2.70028$$gVol. 11, no. 1, p. e70028$$n1$$pe70028$$tAlzheimer's & dementia / Translational research & clinical interventions$$v11$$x2352-8737$$y2025
000274067 8564_ $$uhttps://pub.dzne.de/record/274067/files/DZNE-2025-00048%20SUP.zip
000274067 8564_ $$uhttps://pub.dzne.de/record/274067/files/DZNE-2025-00048.pdf$$yOpenAccess
000274067 8564_ $$uhttps://pub.dzne.de/record/274067/files/DZNE-2025-00048.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000274067 909CO $$ooai:pub.dzne.de:274067$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000274067 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810763$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000274067 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001134$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000274067 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000040$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000274067 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2290613$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b17$$kDZNE
000274067 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000274067 9141_ $$y2025
000274067 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000274067 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2023-08-25
000274067 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZH DEMENT-TRCI : 2022$$d2023-08-25
000274067 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000274067 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-04-16T15:13:10Z
000274067 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-04-16T15:13:10Z
000274067 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-25
000274067 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000274067 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-25
000274067 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000274067 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-04-16T15:13:10Z
000274067 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-25
000274067 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000274067 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-25
000274067 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000274067 9201_ $$0I:(DE-2719)5000067$$kAG Michalowsky$$lPatient-Reported Outcomes and Health Economics Research$$x0
000274067 9201_ $$0I:(DE-2719)1510600$$kAG Hoffmann$$lTranslational Health Care Research$$x1
000274067 9201_ $$0I:(DE-2719)1510800$$kAG Thyrian$$lInterventional Health Care Research (IHCR)$$x2
000274067 980__ $$ajournal
000274067 980__ $$aVDB
000274067 980__ $$aUNRESTRICTED
000274067 980__ $$aI:(DE-2719)5000067
000274067 980__ $$aI:(DE-2719)1510600
000274067 980__ $$aI:(DE-2719)1510800
000274067 9801_ $$aFullTexts